Edwards Lifesciences Co. (NYSE:EW) VP Sells $327,850.00 in Stock

Edwards Lifesciences Co. (NYSE:EW) VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total value of $327,850.00. Following the completion of the sale, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $3,077,593.52. This trade represents a 9.63 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Edwards Lifesciences Stock Performance

Shares of NYSE:EW opened at $67.76 on Friday. The business’s fifty day moving average price is $67.42 and its two-hundred day moving average price is $76.37. Edwards Lifesciences Co. has a fifty-two week low of $58.93 and a fifty-two week high of $96.12. The stock has a market capitalization of $39.96 billion, a price-to-earnings ratio of 9.78, a price-to-earnings-growth ratio of 3.74 and a beta of 1.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting the consensus estimate of $0.67. The company had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The business’s revenue for the quarter was up 8.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.59 earnings per share. As a group, analysts predict that Edwards Lifesciences Co. will post 2.57 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on EW shares. StockNews.com lowered Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Thursday, July 25th. JPMorgan Chase & Co. boosted their target price on Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a report on Friday, October 25th. Truist Financial reduced their target price on Edwards Lifesciences from $71.00 to $70.00 and set a “hold” rating for the company in a report on Friday, October 25th. Wells Fargo & Company cut their price target on Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating for the company in a report on Monday, September 9th. Finally, TD Cowen lowered Edwards Lifesciences from a “buy” rating to a “hold” rating and cut their price target for the stock from $100.00 to $70.00 in a report on Thursday, July 25th. Seventeen investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $75.67.

Institutional Trading of Edwards Lifesciences

Several large investors have recently made changes to their positions in the business. Conway Capital Management Inc. bought a new stake in shares of Edwards Lifesciences during the third quarter worth $737,000. LRI Investments LLC boosted its holdings in Edwards Lifesciences by 1,902.3% in the third quarter. LRI Investments LLC now owns 13,956 shares of the medical research company’s stock valued at $921,000 after acquiring an additional 13,259 shares during the last quarter. Geller Advisors LLC boosted its holdings in Edwards Lifesciences by 7.0% in the third quarter. Geller Advisors LLC now owns 3,546 shares of the medical research company’s stock valued at $234,000 after acquiring an additional 233 shares during the last quarter. Public Employees Retirement System of Ohio boosted its holdings in Edwards Lifesciences by 8.2% in the third quarter. Public Employees Retirement System of Ohio now owns 300,202 shares of the medical research company’s stock valued at $19,810,000 after acquiring an additional 22,731 shares during the last quarter. Finally, Glass Jacobson Investment Advisors llc bought a new position in Edwards Lifesciences in the third quarter valued at about $162,000. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.